Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 3/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | TFPI | P10646 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | NPY4R | P50391 | 14/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.45 |
| ▸ | NPY1R | P25929 | 9/20 | 0.45 |
| ▸ | NPY2R | P49146 | 6/20 | 0.45 |
| ▸ | PCSK6 | P29122 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29886744 | 0.92 | TFPI (0.48) | FURINPRSS1TFPIRXFP1NPY4R | |
| SCHEMBL30881182 | 0.92 | TFPI (0.46) | FURINTFPINPY4RNPY5RNPY1R | |
| SCHEMBL30543180 | 0.89 | NPY4R (0.52) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL30371101 | 0.89 | NPY4R (0.52) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL6850341 | 0.89 | FURIN (0.40) | FURINPRSS1TFPINPY4RNPY5R | |
| SCHEMBL6850333 | 0.89 | FURIN (0.40) | FURINPRSS1TFPINPY4RNPY5R | |
| SCHEMBL31670624 | 0.88 | TFPI (0.49) | FURINPRSS1TFPIRXFP1NPY4R | |
| SCHEMBL29531521 | 0.88 | TFPI (0.45) | FURINPRSS1TFPIRXFP1NPY4R | |
| SCHEMBL29435094 | 0.88 | SLC15A2 (0.45) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL30148473 | 0.88 | FURIN (0.46) | FURINPRSS1TFPIRXFP1NPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260091097-A1 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250381281-A1 | METHODS OF MANUFACTURING PEPTIDE-BASED VACCINES | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250242015-A1 | SELF-ASSEMBLING NANOPARTICLES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2025-07-31 | — | — | US | disclosed |
| US-12370255-B2 | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250127887-A1 | Self-Assembling Nanoparticles Based On Amphiphilic Peptides | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-20240269269-A1 | Self-Assembling Nanoparticles | VACCITECH NORTH AMERICA, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| CN-118103059-A | Self-assembled nanoparticles based on amphiphilic peptides | 巴林萨斯生物疗法北美公司 | 2024-05-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127887-A1 | Self-Assembling Nanoparticles Based On Amphiphilic Peptides | IAPP, BRCA1, ANXA11 | FURIN 226/4885PRSS1 732/4885TFPI 4467/4885 |
| US-20240269269-A1 | Self-Assembling Nanoparticles | UBE2B, CD4, UBE2G2 | FURIN 320/4885PRSS1 1876/4885TFPI 3586/4885 |
| US-20260091097-A1 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | IL2, IFNG, ICOS | FURIN 2348/4885PRSS1 757/4885TFPI 185/4885 |
| US-20250242015-A1 | SELF-ASSEMBLING NANOPARTICLES | UBE2B, CD4, HRH1 | FURIN 327/4885PRSS1 1873/4885TFPI 3551/4885 |
| US-20250381281-A1 | METHODS OF MANUFACTURING PEPTIDE-BASED VACCINES | VIP, HM13, SPPL2B | FURIN 6/4885PRSS1 1548/4885TFPI 1210/4885 |
| US-12370255-B2 | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response | MYD88, ICOS, CD4 | FURIN 16/4885PRSS1 814/4885TFPI 2280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.